MB and ductal breast carcinoma in situ: Using a validated monoclonal Mb antibody (Supplementary Figure S1), we next analysed Mb expression on tissue microarrays containing normal tissue (n=56), intratumoural DCIS (n=155), invasive breast cancer (n=917, clinicopathological parameters are given in Table 1) and 76 recurrences of invasive tumours.